Federal Capture Intelligence

Top HHS pharmaceutical preparation manufacturing contractors (NAICS 325412)

Contract actions: October 1, 2021 – October 4, 2026 Updated October 5, 2026 Department of Health and Human Services agency guide NAICS 325412 · Pharmaceutical Preparation Manufacturing
Latest 12 months
$646.3M
Net obligations · Down $470.7M vs. $1.1B preceding
Prime contractors
56
With positive obligations in the latest 12 months

Research the HHS federal contracting market for pharmaceutical preparation manufacturing under NAICS 325412. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.

Contract obligation trends for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Federal records show $5.8B in net obligations across 1,167 awards in Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services from Oct 1, 2021 through Oct 4, 2026. This market accounts for 3.9% of $150.0B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations decreased 42.1% from $1.1B to $646.3M. 8 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY27 is year-to-date through Oct 4, 2026; earlier years show complete fiscal-year totals.

FY27 year-to-date: $0 versus $0 through the same date in FY26 (Not comparable).
Net obligations · complete fiscal yearNet obligations · FY27 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B493Complete
FY2023$1.1B492Complete
FY2024$913.1M418Complete
FY2025$1.1B360Complete
FY2026$646.3M283Complete

Market at a glance

All reported prime contract awards
All-period net obligations
$5.8B
1,167 awards · 208 prime contractors
Latest 12-month movement
−42.1%
$646.3M vs. $1.1B
Leading eight prime share
82.5%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
3.9% of $150.0B in agency-wide net obligations.
Set-aside share when reported
8.2% of 512 awards with reported set-aside status.
Set-aside reporting
42 set aside · 470 no set-aside · 655 not reported

What changed in the last 12 months?

Oct 5, 2025–Oct 4, 2026, compared with Oct 5, 2024–Oct 4, 2025.

Competitive shifts

PHLOW CORP. gained the most market share
0.6%→14.3%+13.7 percentage points
The contractor now ranks #2 by positive obligations, based on 19 reported actions.
ALVOGEN, INC. had no reported activity in the latest 12 months
$227.7M→$0No latest-period activity
It previously ranked #1 by positive obligations, based on 2 reported actions.
MCKESSON CORPORATION had the largest decline in reported obligations
$196.4M→$80.2M−$116.2M
The contractor now ranks #4 by positive obligations and accounts for 10.9% of positive obligations, based on 54 reported actions.

Buyer demand

Reported obligations through ASPR/ORM-SNS decreased
$530.5M→$228.5M−$302.0M
Latest-period activity spans 19 awards across 16 prime contractors.
Reported obligations through ASPR/DAAPPO/ORM HQ increased
$9.5M→$105.7M+$96.2M
Latest-period activity spans 4 awards across 2 prime contractors.

Award activity

BAVARIAN NORDIC A/S received an unusually large obligation action
$97.0MMay 11, 2026 action
Reported under PIID HHSO100201700019C by BARDA - ASPR / DAAPPO / BARDA DCMA. Award net obligations after the action: $1.3B.
View supporting award
View 4 additional material changes

Competitive shifts

MERIDIAN MEDICAL TECHNOLOGIES, LLC fell the most in the contractor rankings
#12→#27Down 15 places
The contractor accounts for 0.060% of positive obligations across 1 reported action.
ELUSYS THERAPEUTICS INC lost the most market share
3.8%→0.0%−3.8 percentage points
The contractor now ranks outside the ranking by positive obligations, based on 3 reported actions.
ALTITUDE TECHNOLOGIES INC. recorded the largest net deobligation
$47.8M→−$47.8M−$95.6M
The contractor now is unranked by positive obligations, based on 1 reported action.

Market structure

Top-five contractor share increased
55.4%→63.8%+8.4 percentage points
Contractors outside the top five now account for 36.2% of positive obligations.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Federal contract obligations by funding office

See how positive obligations were attributed across funding offices in the 12 months ending Oct 4, 2026.

34.0% of positive obligations were attributed to ASPR/ORM-SNS. That represents $228.5M, down $302.0M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. ASPR/ORM-SNS34.0% · $228.5M · down $302.0M
  2. INDIAN HEALTH SERVICE16.1% · $108.0M · up $70.3M
  3. ASPR/DAAPPO/ORM HQ15.7% · $105.7M · up $96.2M
  4. BARDA - ASPR / DAAPPO / BARDA DCMA14.8% · $99.4M · down $103.3M
  5. NATIONAL INSTITUTES OF HEALTH - CC10.4% · $69.6M · down $34.2M
  6. All other reported offices9.0% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    ASPR/ORM-SNS

    #1Rank unchanged

    Latest 12 months

    $228.5M

    34.0% of positive obligations

    Versus preceding 12 months

    −$302.0M

    16 active prime contractors · 19 awards

    View office comparison and evidence

    Reported obligations decreased 56.9% from $530.5M to $228.5M. The office’s share of positive obligations moved from 47.5% to 34.0%, a change of −13.5 percentage points.

    The latest period contains 32 actions across 19 awards and 2 newly active prime contractors. The preceding period contained 23 active prime contractors and 29 awards.

    Leading award-level changes

  2. Reported funding office

    INDIAN HEALTH SERVICE

    #2Up 5 from #7

    Latest 12 months

    $108.0M

    16.1% of positive obligations

    Versus preceding 12 months

    +$70.3M

    4 active prime contractors · 30 awards

    View office comparison and evidence

    Reported obligations increased 186.9% from $37.6M to $108.0M. The office’s share of positive obligations moved from 3.4% to 16.1%, a change of +12.7 percentage points.

    The latest period contains 31 actions across 30 awards. The preceding period contained 7 active prime contractors and 22 awards.

  3. Reported funding office

    ASPR/DAAPPO/ORM HQ

    #3Up 5 from #8

    Latest 12 months

    $105.7M

    15.7% of positive obligations

    Versus preceding 12 months

    +$96.2M

    2 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations increased 1011.7% from $9.5M to $105.7M. The office’s share of positive obligations moved from 0.85% to 15.7%, a change of +14.9 percentage points.

    The latest period contains 22 actions across 4 awards. The preceding period contained 2 active prime contractors and 8 awards.

    Leading award-level changes

  4. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #4Down 2 from #2

    Latest 12 months

    $99.4M

    14.8% of positive obligations

    Versus preceding 12 months

    −$103.3M

    10 active prime contractors · 10 awards

    View office comparison and evidence

    Reported obligations decreased 50.9% from $202.7M to $99.4M. The office’s share of positive obligations moved from 18.1% to 14.8%, a change of −3.4 percentage points.

    The latest period contains 11 actions across 10 awards and 4 newly active prime contractors. The preceding period contained 10 active prime contractors and 10 awards.

  5. Reported funding office

    NATIONAL INSTITUTES OF HEALTH - CC

    #5Down 2 from #3

    Latest 12 months

    $69.6M

    10.4% of positive obligations

    Versus preceding 12 months

    −$34.2M

    23 active prime contractors · 33 awards

    View office comparison and evidence

    Reported obligations decreased 32.9% from $103.7M to $69.6M. The office’s share of positive obligations moved from 9.3% to 10.4%, a change of +1.1 percentage points.

    The latest period contains 41 actions across 33 awards and 14 newly active prime contractors. The preceding period contained 14 active prime contractors and 40 awards.

  6. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #6Rank unchanged

    Latest 12 months

    $51.4M

    7.7% of positive obligations

    Versus preceding 12 months

    −$10.2M

    6 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations decreased 16.6% from $61.6M to $51.4M. The office’s share of positive obligations moved from 5.5% to 7.7%, a change of +2.1 percentage points.

    The latest period contains 18 actions across 7 awards and 4 newly active prime contractors. The preceding period contained 3 active prime contractors and 3 awards.

  7. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #7Up 4 from #11

    Latest 12 months

    $2.4M

    0.35% of positive obligations

    Versus preceding 12 months

    +$575K

    2 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations increased 32.3% from $1.8M to $2.4M. The office’s share of positive obligations moved from 0.16% to 0.35%, a change of +0.2 percentage points.

    The latest period contains 4 actions across 4 awards and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 2 awards.

  8. Reported funding office

    PHOENIX AREA INDIAN HEALTH SVC

    #8Down 3 from #5

    Latest 12 months

    $1.8M

    0.27% of positive obligations

    Versus preceding 12 months

    −$62.8M

    4 active prime contractors · 8 awards

    View office comparison and evidence

    Reported obligations decreased 97.2% from $64.6M to $1.8M. The office’s share of positive obligations moved from 5.8% to 0.27%, a change of −5.5 percentage points.

    The latest period contains 11 actions across 8 awards. The preceding period contained 6 active prime contractors and 37 awards.

  9. Reported funding office

    OMAS STRATEGIC BUYING CENTER - HHS MISSION

    #9New to the positive-obligation ranking

    Latest 12 months

    $1.5M

    0.22% of positive obligations

    Versus preceding 12 months

    +$1.5M

    3 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations rose from $0 to $1.5M. The office’s share of positive obligations moved from 0% to 0.22%, a change of +0.2 percentage points.

    The latest period contains 5 actions across 4 awards and 3 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.

  10. Reported funding office

    NIH NCI

    #10Up 4 from #14

    Latest 12 months

    $1.4M

    0.21% of positive obligations

    Versus preceding 12 months

    +$615K

    4 active prime contractors · 8 awards

    View office comparison and evidence

    Reported obligations increased 77.7% from $791K to $1.4M. The office’s share of positive obligations moved from 0.070% to 0.21%, a change of +0.1 percentage points.

    The latest period contains 9 actions across 8 awards and 3 newly active prime contractors. The preceding period contained 5 active prime contractors and 14 awards.

  11. Reported funding office

    NAVAJO AREA INDIAN HEALTH SVC

    No positive-obligation rank

    Latest 12 months

    −$25.0M

    0% of positive obligations

    Versus preceding 12 months

    −$120.7M

    8 active prime contractors · 29 awards

    View office comparison and evidence

    Reported obligations moved from $95.6M in net obligations to $25.0M in net deobligations. The office’s share of positive obligations moved from 8.6% to 0%, a change of −8.6 percentage points.

    The latest period contains 34 actions across 29 awards and 5 newly active prime contractors. The preceding period contained 7 active prime contractors and 47 awards.

Contract types, competition, and procurement methods

From Oct 5, 2025 through Oct 4, 2026, 99 awards had positive obligations totaling $772.0M. Only One Source was the leading reported procedure, accounting for 29.6% of positive obligations. Awards with a reported parent IDV accounted for 27.8%. Reported awards used contract vehicles such as VA FSS Schedule 65IB.

Leading award type
71.7%
Definitive Contract
Leading reported procedure
29.6%
Only One Source
Reported parent IDV
27.8%
of positive obligations had a reported parent IDV
Median reported offers
1
60 of 99 awards reported offers

Observed contract vehicles

Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.

Buying method changes

Compared with Oct 5, 2024–Oct 4, 2025. Based on 99 current awards and 153 preceding awards with positive net obligations.

Reported full-and-open obligation share
33.7%
Down from 69.6% in the preceding period
Multiple-award parent obligation share
12.9%
Down from 40.2% in the preceding period
Median positive award obligations
$350K
Down from $800K in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

Same-NAICS comparison

Compared with the NAICS 325412 peer median, parent-IDV obligation share is 70.6 percentage points lower, reported full-and-open obligation share is 10.5 percentage points lower, delivery-order obligation share is 70.5 percentage points lower, and median positive award obligations are 2992.1% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share27.8%98.4%-70.6 pts
Reported full-and-open obligation share33.7%44.1%-10.5 pts
Delivery-order obligation share27.7%98.2%-70.5 pts
Median positive award obligations$350K$11K+2992.1%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)16$553.7M71.7%
Delivery Order(C)52$213.7M27.7%
Purchase Order(B)28$3.7M0.48%
BPA Call(A)3$900K0.12%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)42$116.8M15.1%
FSS(C)10$96.8M12.5%
BPA(E)3$900K0.12%
Not reported44$557.4M72.2%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Single Award(S)41$115.2M14.9%
Multiple Award(M)14$99.4M12.9%
Not reported44$557.4M72.2%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Only One Source(SSS)5$228.3M29.6%
Sss(ONLY ONE SOURCE)4$219.3M28.4%
Negotiated Proposal/Quote(NP)32$171.1M22.2%
Subject to Multiple Award Fair Opportunity(MAFO)7$89.5M11.6%
Np(NEGOTIATED PROPOSAL/QUOTE)11$50.4M6.5%
Mafo(SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY)6$9.8M1.3%
Other reported values34$3.6M0.47%

Extent competed

Reported valueAwardsPositive obligationsShare
Full and Open Competition(A)37$259.9M33.7%
Not Competed(C)5$228.3M29.6%
C(NOT COMPETED)4$219.3M28.4%
A(FULL AND OPEN COMPETITION)15$58.9M7.6%
D(FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES)2$1.3M0.17%
Competed Under SAP(F)14$1.3M0.17%
Other reported values22$3.1M0.40%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Only One Source - Other(ONE)5$58.7M7.6%
Urgency(URG)1$30.0M3.9%
Fair Opportunity Given(FAIR)6$10.4M1.3%
Other Statutory Authority(OSA)1$132K0.020%
Not reported86$672.7M87.1%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)7$288.5M37.4%
Mobilization, Essential R&d (FAR 6.302-3)(MES)1$105.3M13.6%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$53.7M7.0%
SAP Non-Competition (FAR 13)(SP2)10$1.2M0.16%
Authorized by Statute (FAR 6.302-5(A)(2)(I))(OTH)1$86K0.010%
Less Than or Equal to the Micro-Purchase Threshold(MPT)1$3K0%
Not reported78$323.1M41.9%

Contract pricing types

Reported valueAwardsPositive obligationsShare
Firm Fixed Price(J)63$489.7M63.4%
J(FIRM FIXED PRICE)28$170.9M22.1%
U(COST PLUS FIXED FEE)6$110.0M14.3%
Cost Plus Fixed Fee(U)2$1.3M0.17%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Drugs and Biologicals(6505)74$558.1M72.3%
R&d- Medical: Biomedical (Commercialized)(AN17)1$105.3M13.6%
Support- Administrative: Mailing/Distribution(R604)1$51.1M6.6%
Medical and Surgical Instruments, Equipment, and Supplies(6515)4$50.2M6.5%
Health R&d Services; Health Care Services; Basic Research(AN11)2$3.6M0.47%
Special Studies/Analysis- Chemical/Biological(B504)2$1.0M0.13%
Other reported values15$2.7M0.35%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)21$522.1M67.6%
Indian Health Service(7527)35$112.0M14.5%
National Institutes of Health(7529)29$84.3M10.9%
Centers for Disease Control and Prevention(7523)7$51.4M6.7%
Office of the Assistant Secretary for Financial Resources(7571)4$1.5M0.19%
Office of the Assistant Secretary for Administration(7570)2$594K0.080%
Other reported values1$28K0.0036%

Awarding offices

Reported valueAwardsPositive obligationsShare
Aspr/Orm-Sns(75A503)14$316.9M41.0%
Indian Health Service(75H711)20$108.4M14.0%
Aspr/Daappo/Orm Hq(75A502)4$105.7M13.7%
Barda - Aspr / Daappo / Barda Dcma(75A501)3$99.4M12.9%
National Institutes of Health Olao(75N980)15$80.7M10.5%
Cdc Office of Acquisition Services(75D301)7$51.4M6.7%
Other reported values36$9.4M1.2%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
36W79720D0001(3600)26$107.0M13.8%
36F79723D0171(3600)1$50.0M6.5%
36F79723D0101(3600)1$30.0M3.9%
V797D70258(3600)1$8.1M1.1%
36F79725D0145(3600)1$7.9M1.0%
36E79726D0010(3600)1$2.7M0.35%
36E79726D0009(3600)1$2.0M0.26%
75N98026D00014(7529)1$1.4M0.18%
Other reported values22$5.6M0.73%
Not reported44$557.4M72.2%

Exact vehicle-match evidence

Reported award data linked 3 awards to a specific catalog vehicle.

Offers, award size, and timing

Median reported offers
1 median
60 reported · 39 not reported
Positive award obligations
$350K median
$82K–$5.5M middle 50%
Reported performance period
364 days (~12 months) median
99 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Oct 4, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Top federal contractors

Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.

Prime contractor concentration
8 of 56prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
16.1%of positive obligations in the last 12 months
Leading four prime contractors
54.5%of positive obligations in the last 12 months
Leading eight prime contractors
82.5%of positive obligations in the last 12 months

Based on $735.4M in positive obligations during the 12 months ending Oct 4, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Oct 5, 2024–Oct 4, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $118.3M

    16.1%

    Dollar movement

    +$4.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for EMERGENT BIOSOLUTIONS CANADA INC
    Obligations: prior → latest
    $114.3M → $118.3M
    +3.5%
    Share: prior → latest
    8.0% → 16.1%
    +8.1 percentage points
    All-period obligations
    $558.4M
    9.5% of all-period positive obligations · 2 awards
    Recorded activity
    Since Oct 22, 2021
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $105.3M

    14.3%

    Dollar movement

    +$96.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    19 actions

    Historical and award details for PHLOW CORP.
    Obligations: prior → latest
    $8.4M → $105.3M
    +1158.2%
    Share: prior → latest
    0.58% → 14.3%
    +13.7 percentage points
    All-period obligations
    $342.4M
    5.8% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 16, 2021
    through Sep 29, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $97.0M

    13.2%

    Dollar movement

    −$46.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for BAVARIAN NORDIC A/S
    Obligations: prior → latest
    $143.6M → $97.0M
    −32.5%
    Share: prior → latest
    10.0% → 13.2%
    +3.2 percentage points
    All-period obligations
    $882.1M
    15.1% of all-period positive obligations · 1 award
    Recorded activity
    Since May 17, 2022
    through May 11, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $80.2M

    10.9%

    Dollar movement

    −$116.2M

    vs. prior 12 months

    Last 12mo awards

    52 awards

    54 actions

    Historical and award details for MCKESSON CORPORATION
    Obligations: prior → latest
    $196.4M → $80.2M
    −59.2%
    Share: prior → latest
    13.7% → 10.9%
    −2.8 percentage points
    All-period obligations
    $691.5M
    11.8% of all-period positive obligations · 368 awards
    Recorded activity
    Since Oct 26, 2021
    through Sep 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside25
    Not reported5075
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $68.3M

    9.3%

    Dollar movement

    −$34.3M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for DLA TROOP SUPPORT
    Obligations: prior → latest
    $102.6M → $68.3M
    −33.4%
    Share: prior → latest
    7.1% → 9.3%
    +2.1 percentage points
    All-period obligations
    $412.1M
    7.0% of all-period positive obligations · 10 awards
    Recorded activity
    Since Oct 18, 2021
    through Sep 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $51.1M

    7.0%

    Dollar movement

    −$10.4M

    vs. prior 12 months

    Last 12mo awards

    1 award

    10 actions

    Historical and award details for MCKESSON SPECIALTY DISTRIBUTION LLC
    Obligations: prior → latest
    $61.5M → $51.1M
    −17.0%
    Share: prior → latest
    4.3% → 7.0%
    +2.7 percentage points
    All-period obligations
    $579.2M
    9.9% of all-period positive obligations · 2 awards
    Recorded activity
    Since Aug 2, 2022
    through Jun 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $50.0M

    6.8%

    Dollar movement

    +$10.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PARTNER THERAPEUTICS, INC.
    Obligations: prior → latest
    $39.1M → $50.0M
    +27.8%
    Share: prior → latest
    2.7% → 6.8%
    +4.1 percentage points
    All-period obligations
    $192.5M
    3.3% of all-period positive obligations · 3 awards
    Recorded activity
    Since Feb 15, 2022
    through Jun 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $36.3M

    4.9%

    Dollar movement

    +$27.2M

    vs. prior 12 months

    Last 12mo awards

    6 awards

    9 actions

    Historical and award details for GLAXOSMITHKLINE, LLC
    Obligations: prior → latest
    $9.1M → $36.3M
    +299.3%
    Share: prior → latest
    0.63% → 4.9%
    +4.3 percentage points
    All-period obligations
    $63.8M
    1.1% of all-period positive obligations · 26 awards
    Recorded activity
    Since Oct 19, 2021
    through Sep 25, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported51
    Reported small business00
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $33.3M

    4.5%

    Dollar movement

    −$53.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for FRESENIUS KABI, LLC
    Obligations: prior → latest
    $86.3M → $33.3M
    −61.4%
    Share: prior → latest
    6.0% → 4.5%
    −1.5 percentage points
    All-period obligations
    $124.3M
    2.1% of all-period positive obligations · 3 awards
    Recorded activity
    Since Feb 28, 2023
    through Aug 31, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported10
    Reported small business00
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    $30.0M

    4.1%

    Dollar movement

    +$30.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for USANTIBIOTICS LLC
    Obligations: prior → latest
    $0 → $30.0M
    Not comparable
    Share: prior → latest
    0% → 4.1%
    +4.1 percentage points
    All-period obligations
    $30.0M
    0.51% of all-period positive obligations · 1 award
    Recorded activity
    Since May 27, 2026
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business10
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $14.5M

    2.0%

    Dollar movement

    +$10.1M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for BAXTER HEALTHCARE CORPORATION
    Obligations: prior → latest
    $4.4M → $14.5M
    +227.4%
    Share: prior → latest
    0.31% → 2.0%
    +1.7 percentage points
    All-period obligations
    $57.4M
    0.98% of all-period positive obligations · 26 awards
    Recorded activity
    Since Dec 6, 2021
    through Aug 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside13
    Not reported12
    Reported small business00
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $12.4M

    1.7%

    Dollar movement

    −$8.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for RAFA LABORATORIES LTD
    Obligations: prior → latest
    $20.9M → $12.4M
    −40.6%
    Share: prior → latest
    1.5% → 1.7%
    +0.2 percentage points
    All-period obligations
    $33.4M
    0.57% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 30, 2025
    through Jul 29, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    $8.1M

    1.1%

    Dollar movement

    $0

    no change vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for HEYLTEX CORPORATION
    Obligations: prior → latest
    $8.1M → $8.1M
    +0.0%
    Share: prior → latest
    0.56% → 1.1%
    +0.5 percentage points
    All-period obligations
    $23.3M
    0.40% of all-period positive obligations · 3 awards
    Recorded activity
    Since Aug 24, 2022
    through Aug 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $7.6M

    1.0%

    Dollar movement

    +$7.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for ACCORD BIOPHARMA, INC.
    Obligations: prior → latest
    $0 → $7.6M
    Not comparable
    Share: prior → latest
    0% → 1.0%
    +1.0 percentage points
    All-period obligations
    $7.6M
    0.13% of all-period positive obligations · 1 award
    Recorded activity
    Since Mar 18, 2026
    through Mar 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $5.6M

    0.76%

    Dollar movement

    +$644K

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for WG CRITICAL CARE, LLC
    Obligations: prior → latest
    $5.0M → $5.6M
    +13.0%
    Share: prior → latest
    0.35% → 0.76%
    +0.4 percentage points
    All-period obligations
    $10.6M
    0.18% of all-period positive obligations · 1 award
    Recorded activity
    Since Aug 27, 2025
    through Aug 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

Potential federal contract recompetes

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

BAVARIAN NORDIC A/S

BAVARIAN NORDIC MOD 21

$1.26B is obligated on an award with a reported potential end date of September 26, 2027.

Performance period

90.2%

As of Oct 4, 2026Potential end Sep 26, 2027

Current award value as a share of potential value

73.9%

$1.3B current$1.7B potential
Supporting data

Reported performance starts Sep 27, 2017.

No later potential end date is reported; current and potential end dates are both Sep 26, 2027.

$1.3B is obligated against $1.3B in current reported award value (100.0%).

Reported potential end dates: Sep 26, 2026 → Sep 26, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700019C

PARTNER THERAPEUTICS, INC.

EXERCISE OPTIONAL ORDERING PERIOD 2 FOR LEUKINE 250MCG VIAL INJECTABLES

The reported potential end date is Mar 29, 2027. Current award value is 100.0% of reported potential value ($133.5M of $133.5M).

Performance period

86.3%

As of Oct 4, 2026Potential end Mar 29, 2027

Current award value as a share of potential value

100.0%

$133.5M current$133.5M potential
Supporting data

Reported performance starts Sep 26, 2023.

No later potential end date is reported; current and potential end dates are both Mar 29, 2027.

$133.5M is obligated against $133.5M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Sep 29, 2027 → Mar 29, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50323F80027

ALVOGEN, INC.

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.

$227.7M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

63.2%

As of Oct 4, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$227.7M current$227.7M potential
Supporting data

Reported performance starts Jun 30, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$227.7M is obligated against $227.7M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80013

DLA TROOP SUPPORT

PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869

$77.4M is obligated on an award with a reported potential end date of April 9, 2027.

Performance period

48.6%

As of Oct 4, 2026Potential end Apr 9, 2027

Current award value as a share of potential value

100.0%

$77.4M current$77.4M potential
Supporting data

Reported performance starts Apr 10, 2026.

No later potential end date is reported; current and potential end dates are both Apr 9, 2027.

$77.4M is obligated against $77.4M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N98026C00026

EXELAN PHARMACEUTICALS INC

OSELTAMIVIR PHOSPHATE 30MG CAPSULES CHANGE NDC FROM NDC 47781-468-13 TO NDC: 76282-0702-45); 10 CT. CAPSULES PACKS.

$74.1M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

63.3%

As of Oct 4, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$74.1M current$74.1M potential
Supporting data

Reported performance starts Jun 28, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$74.1M is obligated against $74.1M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80014

USANTIBIOTICS LLC

AMOXICILLIN TRIHYDRATE 500MG 60 CT AND 100 CT ORAL CAPSULES

$30.0M is obligated on an award with a reported potential end date of May 28, 2027.

Performance period

35.2%

As of Oct 4, 2026Potential end May 28, 2027

Current award value as a share of potential value

100.0%

$30.0M current$30.0M potential
Supporting data

Reported performance starts May 29, 2026.

No later potential end date is reported; current and potential end dates are both May 28, 2027.

$30.0M is obligated against $30.0M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50326F80004

These are research leads, not confirmed recompetes. USAspending records through Oct 4, 2026; reported dates and values can change through later modifications.

Recent federal contract award activity

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Modification

This action

+$53.9M

PHLOW CORP.

ASPR/DAAPPO/ORM HQ

THE PURPOSE OF THIS ACTION IS TO FUND THE REMAINING APIS FOR THE STRATEGIC RESERVE

Why it stands out

The contractor climbed 18 positions in this market.

It now ranks #2 by positive obligations over the latest 12 months.

Award net obligations
$696.7M
Share of 12-month positive obligations
7.3%
Supporting data
Prime contractor
#2 · 14.3% share
up 18 ranks · +13.7 percentage points · $96.9M net increase; action accounted for 55.6%
Funding office
#3 · 15.7% attributed share
up 5 ranks · +14.9 percentage points · $96.2M net increase; action accounted for 56.0%
Related:Largest share gainFunding office gain
PIID 75A50120C00092 · Mod P00027
Modification

This action

+$97.0M

BAVARIAN NORDIC A/S

BARDA - ASPR / DAAPPO / BARDA DCMA

BAVARIAN NORDIC MOD 21

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $97.0M while office-attributed obligations fell $103.3M overall.

Award net obligations
$1.3B
Share of 12-month positive obligations
13.2%
Supporting data
Prime contractor
#3 · 13.2% share
$46.6M net decline despite this positive action
Funding office
#4 · 14.8% attributed share
$103.3M net decline despite this positive action
Related:Unusually large action
PIID HHSO100201700019C · Mod P00021
Modification

This action

+$64.5M

EMERGENT BIOSOLUTIONS CANADA INC

ASPR/ORM-SNS

EO14042 BOTULISM ANTITOXIN

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $64.5M while office-attributed obligations fell $302.0M overall.

Award net obligations
$320.9M
Share of 12-month positive obligations
8.8%
Supporting data
Funding office
#1 · 34.0% attributed share
$302.0M net decline despite this positive action
PIID 75A50119C00075 · Mod P00015
Deobligation

This action

−$40.6M

CHARTWELL RX LLC

ASPR/ORM-SNS

THE PURPOSE OF THIS MODIFICATION IS TO DESCOPE AMOXICILLIN TRIHYDRATE 500 MG CLINS.

Why it stands out

This award recorded a material contraction.

The action removed $40.6M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$99.0M
Share of 12-month positive obligations
5.5%
Supporting data
Prime contractor
0% share
−8.0 percentage points · $155.4M net decline; action accounted for 26.1%
PIID 75A50322F80030 · Mod P00007
Modification

This action

+$51.0M

MCKESSON SPECIALTY DISTRIBUTION LLC

CDC OFFICE OF ACQUISITION SERVICES

CENTRALIZED VACCINE DISTRIBUTION

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $51.0M while office-attributed obligations fell $10.2M overall.

Award net obligations
$203.9M
Share of 12-month positive obligations
6.9%
Supporting data
Prime contractor
#6 · 7.0% share
$10.4M net decline despite this positive action
Funding office
#6 · 7.7% attributed share
$10.2M net decline despite this positive action
PIID 75D30123C17978 · Mod P00012
Modification

This action

+$50.0M

DLA TROOP SUPPORT

NATIONAL INSTITUTES OF HEALTH - CC

PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472]

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $50.0M while office-attributed obligations fell $34.2M overall.

Award net obligations
$77.4M
Share of 12-month positive obligations
6.8%
Supporting data
Prime contractor
#5 · 9.3% share
$34.3M net decline despite this positive action
Funding office
#5 · 10.4% attributed share
$34.2M net decline despite this positive action
PIID 75N98026C00026 · Mod P00001
View recent award activity by date (10)
  1. GLAXOSMITHKLINE, LLCModification · PIID 75A50325C00019
    Action+$18.2M
    Award net obligations$45.5M
  2. GE PRECISION HEALTHCARE LLCBase award · PIID 75N98026P01826
    Action+$205K
    Award net obligations$205K
  3. DLA TROOP SUPPORTModification · PIID 75N98026C00026
    Action+$580K
    Award net obligations$77.4M
  4. DLA TROOP SUPPORTModification · PIID 75N98026C00026
    Action+$11.8M
    Award net obligations$77.4M
  5. GOVERNMENT SCIENTIFIC SOURCE INCBase award · PIID 75D30126P21626
    Action+$47K
    Award net obligations$47K
  6. SERB MEDICAL SOLUTIONS INC.Base award · PIID 7571MN26P00085
    Action+$37K
    Award net obligations$37K
  7. GLAXOSMITHKLINE, LLCDeobligation · PIID 75D30126F21661
    Action−$17K
    Award net obligations$58K
  8. PROGENICS PHARMACEUTICALS INCBase award · PIID 75N98026F00001
    Action+$93K
    Award net obligations$93K
  9. GLAXOSMITHKLINE, LLCBase award · PIID 75D30126F21661
    Action+$75K
    Award net obligations$58K
  10. MEDKOO INCDeobligation · PIID 75N95021P00528
    Action−$114K
    Award net obligations$567K

HHS pharmaceutical preparation manufacturing market FAQs

Answers based on reported federal contract data.

Who are the top HHS pharmaceutical preparation manufacturing contractors?

In the 12 months through October 4, 2026, EMERGENT BIOSOLUTIONS CANADA INC, PHLOW CORP., and BAVARIAN NORDIC A/S were the leading HHS pharmaceutical preparation manufacturing prime contractors by positive obligations.

  1. #1

    EMERGENT BIOSOLUTIONS CANADA INC

    $118,251,472 in positive obligations

  2. #2

    PHLOW CORP.

    $105,274,409 in positive obligations

  3. #3

    BAVARIAN NORDIC A/S

    $96,961,504 in positive obligations

Rankings use reported USAspending award data.

Did HHS contract obligations decrease in the pharmaceutical preparation manufacturing market?

Yes. Measured by net prime contract obligations, reported HHS activity in the pharmaceutical preparation manufacturing market decreased 42.1% from $1,117,012,212 in the preceding 12 months to $646,271,706 in the 12 months through October 4, 2026.

Latest 12 months
$646,271,706
Net prime contract obligations
Preceding 12 months
$1,117,012,212
Net prime contract obligations
Change
−42.1%
Between matched 12-month periods

Reported contract actions, not outlays or a forecast.

What recent HHS contract award activity was reported in the pharmaceutical preparation manufacturing market?

Recent HHS contract award activity reported in the pharmaceutical preparation manufacturing market included actions for PHLOW CORP., BAVARIAN NORDIC A/S, and EMERGENT BIOSOLUTIONS CANADA INC during the 12 months through October 4, 2026.

Action obligations are transaction-level amounts, not current award-level obligations.

Which procurement methods were reported for HHS contracts under NAICS 325412?

From October 5, 2025 through October 4, 2026, HHS reported 99 positive-obligation awards for pharmaceutical preparation manufacturing under NAICS 325412. The leading award type was definitive contract. The leading reported procedure was only one source.

Positive-obligation awards
99
Leading reported procedure
Only One Source
29.6% of positive obligations
Leading award type
Definitive Contract
71.7% of positive obligations
Full and open
33.7%
of positive obligations
Reported parent IDV
27.8%
of positive obligations
Observed vehicles
VA FSS Schedule 65IB
Exact matches from reported parent PIIDs

Percentages use positive obligations as the denominator.

Which HHS pharmaceutical preparation manufacturing awards may warrant recompete research?

6 HHS pharmaceutical preparation manufacturing awards may warrant recompete research based on reported potential-end dates, including awards held by BAVARIAN NORDIC A/S, PARTNER THERAPEUTICS, INC., and ALVOGEN, INC.

Research leads, not confirmed recompetes. Dates may change through later modifications.

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Reported obligations include contract actions from October 1, 2021 through October 4, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology